MIAMI BEACH -- The surgical dogma favoring axillary dissection in breast cancer continues to give way to more selective data-driven strategies that allow more women to avoid axillary surgery, an ...

The word "dissection" may conjure images of a high school biology lab full of frogs or sheep's eyeballs in various stages of deconstruction. But an axillary node dissection is a decidedly different ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

This Canadian study included 111 women (median age 63 years), most of whom (90%, n=100) had invasive ductal carcinoma. Over the entire cohort, more than half (54%, n=60) underwent mastectomy and 46% ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who have one positive sentinel node and no high-risk features can likely be spared ...

The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer Axillary dissection is the standard management of the axilla in invasive ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Axillary radiotherapy and axillary lymph node dissection appeared associated with excellent and ...

Patients with breast cancer routinely undergo complete axillary lymph-node dissection (ALND) as part of the surgical approach to treatment. Whether it is necessary to remove this often healthy tissue ...

A total of 333 patients were included in the study. The SLN could be identified in 328 out of 333 patients, calculating an identification rate of 98.5%. SLNs were positive for metastases in 128 out of ...